← Research library

Thymopentin versus placebo in a 91-person HIV trial

Randomized study in people · 1992

What was studied
91 enrolled across three sites. The conference report gives 47 thymopentin and 44 placebo. The journal report gives 52 asymptomatic and 39 symptomatic participants, with 45 assigned to 24 weeks and 46 to 52 weeks of blinded evaluation.
Main finding
Progression to symptoms among asymptomatic participants · 0 versus 2 through week 24 (placebo Kaplan–Meier estimate 9.1%, p=0.12). The journal abstract reports one additional placebo event in the 52-week subset.

Reported findings and study design

Reported findings

Randomized, double-blind comparison of 50 mg thymopentin or placebo subcutaneously three times weekly. Randomization was stratified by baseline HIV symptoms.

Population or model 91 enrolled across three sites. The conference report gives 47 thymopentin and 44 placebo. The journal report gives 52 asymptomatic and 39 symptomatic participants, with 45 assigned to 24 weeks and 46 to 52 weeks of blinded evaluation.

Dose, route and schedule

Randomized, double-blind comparison of 50 mg thymopentin or placebo subcutaneously three times weekly. Randomization was stratified by baseline HIV symptoms.

Protocol source ↗ · Original journal abstract and the investigators’ 1990 conference abstract L411, p. 148.

Results · Original journal abstract and the investigators’ 1990 conference abstract L411, p. 148.
MeasureResultComparison, timing and statistics
Progression to symptoms among asymptomatic participants0 versus 2 through week 24 (placebo Kaplan–Meier estimate 9.1%, p=0.12). The journal abstract reports one additional placebo event in the 52-week subset.
CD4 measures among asymptomatic participantsThe area under the percent-CD4 curve favored thymopentin (p=0.03), as did time to a 20% rise in percent CD4 (p=0.04) through week 24.
Progression to AIDS among symptomatic participantsThe journal report gives two events in each arm. It reports no serious adverse effects attributed to thymopentin.

The matching 1990 conference report supplies arm sizes and gives a more favorable early combined progression count. The later journal report gives different outcomes by symptom group. Few clinical events and subgroup analyses limit the interpretation.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The matching 1990 conference report supplies arm sizes and gives a more favorable early combined progression count. The later journal report gives different outcomes by symptom group. Few clinical events and subgroup analyses limit the interpretation.

Related publications may describe some of the same participants or experiments.

Source details

Original journal abstract and the investigators’ 1990 conference abstract L411, p. 148.

Sources checked

Added to the library

Citation

Randomized trialEnglish abstract

M. A. Conant, L. H. Calabrese, S. E. Thompson, B. J. Poiesz, S. Rasheed, R. L. Hirsch, L. A. Meyerson, A. B. Kremer, C. C. Wang, G. Goldstein. Thymopentin versus placebo in a 91-person HIV trial AIDS 6(11), 1335–1339

Study source ↗ · DOI 10.1097/00002030-199211000-00016 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards